AURKA and small cell lung carcinoma: In another study, a randomized phase II trial of paclitaxel combined with the selective Aurora kinase A inhibitor, Alisertib (MLN8237; Takeda) demonstrated significant efficacy in comparison to paclitaxel plus placebo as a second-line treatment for small-cell lung cancer (SCLC) [251].